This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Discussing Novo Nordisk's Wegovy® (semaglutide) approval in the US for the treatment Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Ticker(s): NVOWho's the expert?
Institution: Private Practice
- Board Certified Gastroenterologist in private practice in Beverly Hills California with over 35 years of experience; fellowship trained at New York Medical college.
- Manages 30+ patients with MASH.
- Clinical focuses is on diarrhea, constipation, abdominal pain, and rectal bleeding, as well as Inflammatory Bowel Disease and GERD.
Interview GoalThis conversation will focus on the standard of care for and recent approval of Novo Nordisk's Wegovy® for the treatment of MASH.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
